Mersana Therapeutics, Inc. (MRSN) — Earnings Call X-Ray
Our AI read all 29 of MRSN's earnings calls (2018–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
F
Q4 2024
Calls Analyzed
29
2018–2025
Avg Candor
5.9/9
evasion 4.4/9
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-15
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of MRSN's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
F
Q4 2024 earnings call
2025-03-03
move ±20.3%
Management held guidance steady. The delivery was rich in specifics, frequently evasive.
Guidance: maintainedMargins: stable 7 analysts · 11 questions
⚑ Critic ammunition⚑ Question left hanging✓ Early product, fast growth⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q3 2024 earnings call
2024-11-13
move ±19.6%
Management held guidance steady against expanding margins. The delivery was frequently evasive.
Guidance: maintainedMargins: expandingHeadcount: cuttingCapex: decreasing 6 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q2 2024 earnings call
2024-08-13
move ±20.3%
Management held guidance steady against contracting margins. The delivery was frequently evasive.
Guidance: maintainedMargins: contractingHeadcount: cutting 9 analysts · 19 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q1 2024 earnings call
2024-05-09
move ±24.2%
Management lowered guidance against expanding margins. The delivery was frequently evasive.
Guidance: loweredMargins: expandingHeadcount: cuttingCapex: decreasing 8 analysts · 17 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q4 2023 earnings call
2024-02-28
move ±25.1%
Management gave no formal guidance against expanding margins. The delivery was unusually candid.
Margins: expandingHeadcount: cuttingCapex: decreasing 8 analysts · 18 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q3 2023 earnings call
2023-11-07
move ±18.3%
Management held guidance steady against contracting margins. The delivery was frequently evasive.
Guidance: maintainedMargins: contractingHeadcount: cutting 6 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q1 2023 earnings call
2023-05-09
move ±22.9%
Management held guidance steady against contracting margins. The delivery was rich in specifics, promotional in tone.
Guidance: maintainedMargins: contractingHeadcount: growing 8 analysts · 18 questions
⚑ Critic ammunition⚑ Question left hanging✓ Prepayments growing⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
YES Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q4 2022 |
2023-02-28 |
D |
maintained | unclear | contracting |
6/9 |
2/9 |
| Q3 2022 |
2022-11-07 |
F |
none | unclear | contracting |
6/9 |
5/9 |
| Q2 2022 |
2022-08-08 |
C |
none | unclear | contracting |
6/9 |
3/9 |
| Q1 2022 |
2022-05-09 |
C |
maintained | unclear | unclear |
7/9 |
4/9 |
| Q4 2021 |
2022-02-28 |
D |
none | unclear | unclear |
6/9 |
4/9 |
| Q3 2021 |
2021-11-09 |
D |
maintained | unclear | unclear |
7/9 |
3/9 |
| Q2 2021 |
2021-08-06 |
D |
maintained | unclear | contracting |
6/9 |
5/9 |
| Q1 2021 |
2021-05-10 |
C |
maintained | unclear | contracting |
6/9 |
4/9 |
| Q4 2020 |
2021-02-26 |
D |
maintained | unclear | contracting |
5/9 |
4/9 |
| Q3 2020 |
2020-11-09 |
D |
maintained | accelerating | unclear |
6/9 |
4/9 |
| Q2 2020 |
2020-08-07 |
C |
raised | unclear | unclear |
6/9 |
4/9 |
| Q1 2020 |
2020-05-08 |
C |
maintained | stable | unclear |
6/9 |
3/9 |
| Q4 2019 |
2020-02-28 |
D |
none | unclear | unclear |
6/9 |
5/9 |
| Q3 2019 |
2019-11-10 |
D |
none | unclear | unclear |
6/9 |
4/9 |
| Q2 2019 |
2019-08-10 |
D |
maintained | unclear | contracting |
6/9 |
3/9 |
| Q1 2019 |
2019-05-12 |
D |
none | unclear | unclear |
6/9 |
4/9 |
| Q4 2018 |
2019-03-08 |
F |
none | unclear | contracting |
5/9 |
4/9 |
| Q3 2018 |
2018-11-13 |
D |
maintained | unclear | contracting |
7/9 |
3/9 |
| Q2 2018 |
2018-08-15 |
F |
none | unclear | unclear |
5/9 |
6/9 |
| Q1 2018 |
2018-05-14 |
D |
none | unclear | contracting |
6/9 |
4/9 |
| Q4 2017 |
2018-03-28 |
D |
none | unclear | contracting |
6/9 |
3/9 |
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← MRRTY All “M” companies
MRT →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.